Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Kazuki TajimaHiroshi Goto

Abstract

To compare the efficacy of topical 1.5% and 0.5% levofloxacin (LVFX) for the treatment of multidrug-resistant Pseudomonas aeruginosa (MDRP) keratitis in rabbits. In a rabbit eye, we produced an MDRP keratitis model by excising a 2-mm circular disc of the cornea up to a depth of one-half of the stromal layer and inoculated an MDRP strain into the corneal concavity. Nine hours after inoculation and after confirming that MDRP keratitis had developed, we treated the eyes topically with 0.5% levofloxacin, 1.5% levofloxacin, or phosphate-buffered saline (PBS) every 6 h until 57 h postinfection. The infected eyes were evaluated by clinical score, histopathological examination, and viable bacterial count (colony forming units). In the MDRP keratitis model, clinical score was significantly lower in 0.5% and 1.5% levofloxacin-treated groups than in PBS-treated group and was the lowest in 1.5% levofloxacin-treated group. Histopathological examination showed maintenance of corneal translucency and little influx of polymorphonuclear neutrophils in 1.5% levofloxacin-treated group. Viable bacterial count in the infected cornea was significantly lower in 0.5% levofloxacin-treated group compared with PBS-treated group, while no viable bacteria ...Continue Reading

References

Nov 1, 1990·Current Eye Research·M K JohnsonS Chen
Mar 1, 1993·Antimicrobial Agents and Chemotherapy·G L DrusanoH C Standiford
May 1, 1993·Antimicrobial Agents and Chemotherapy·A ForrestJ J Schentag
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Feb 28, 2001·Burns : Journal of the International Society for Burn Injuries·M W DouglasT Gottlieb
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
May 23, 2002·Antimicrobial Agents and Chemotherapy·D Andes, W A Craig
Aug 21, 2002·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Geir BukholmNils Smith-Erichsen
May 27, 2003·Investigative Ophthalmology & Visual Science·Wolfram SchreiberWolfgang Behrens-Baumann
Dec 29, 2004·International Journal of Antimicrobial Agents·Jian LiKingsley Coulthard
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew E Falagas, Sofia K Kasiakou
Aug 26, 2006·The Lancet Infectious Diseases·Jian LiDavid L Paterson
Jan 17, 2009·The Journal of Antimicrobial Chemotherapy·Nobumasa AokiKeizo Yamaguchi
Jul 14, 2010·Cornea·H Dwight CavanaghJames V Jester
Sep 13, 2011·Annals of Intensive Care·Argyris S Michalopoulos, Matthew E Falagas
Nov 26, 2011·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Verena ProkoschTobias Stupp
Aug 21, 2012·Cornea·Elvin H YildizElisabeth J Cohen
Nov 7, 2012·Veterinary Ophthalmology·Kazuki TajimaNorihiko Ito
Apr 15, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuki TajimaHiroshi Goto
Aug 16, 2014·Investigative Ophthalmology & Visual Science·Cynthia WeiDanielle M Robertson

❮ Previous
Next ❯

Software Mentioned

MicroScan

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.